Drug interactions
Buprenorphine transdermal + Ipratropium-salbutamol
Severity: Minor
Buprenorphine transdermal and Ipratropium-salbutamol: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Transdermal buprenorphine carries labeled QT-prolongation cautions, and high-dose salbutamol can cause hypokalemia and tachycardia. The combined risk is generally small at usual inhaled doses but matters in patients with other QT risk factors.
What this interaction means in plain words
Buprenorphine transdermal and Ipratropium-salbutamol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Possible additive QT effects, with beta-2 agonist-induced hypokalemia as a contributing factor.
What to do
No routine action is needed; check potassium and consider an ECG if high-dose salbutamol is used or other QT-prolonging drugs or risk factors are present.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine transdermal and Ipratropium-salbutamol, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipratropium-salbutamol
Frequently asked questions
Can I take Buprenorphine transdermal with Ipratropium-salbutamol?
MediHelp rates the interaction as minor. Buprenorphine transdermal and Ipratropium-salbutamol have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Transdermal buprenorphine carries labeled QT-prolongation cautions, and high-dose salbutamol can cause hypokalemia and tachycardia. The combined risk is generally small at usual inhaled doses but matters in patients with other QT risk factors.
How serious is the interaction between Buprenorphine transdermal and Ipratropium-salbutamol?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine action is needed; check potassium and consider an ECG if high-dose salbutamol is used or other QT-prolonging drugs or risk factors are present.
What other medicines interact with Ipratropium-salbutamol?
MediHelp also lists interactions of Ipratropium-salbutamol with, for example, Amisulpride, Arsenic trioxide, Carvedilol. The full list is on the Ipratropium-salbutamol page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
